Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy.

Trial Profile

Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2015

At a glance

  • Drugs Canakinumab; Colchicine
  • Indications Gout
  • Focus Therapeutic Use
  • Acronyms H2251
  • Sponsors Novartis
  • Most Recent Events

    • 12 Apr 2011 Last checked against ClinicalTrials.gov record.
    • 21 Jun 2010 New trial record
    • 18 Jun 2010 Preliminary results were presented at EULAR 2010, according to a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top